

Supplement table 1: Drugs included in the study described as groups, subgroups and at specific drug level including ATC codes.

Groups	Subgroups	Specific drugs	ATC codes
Anticoagulants + antiplatelet drugs			B01
	Any anticoagulants		B01AA + B01AE + B01AF
		Warfarin	B01AA03
	New oral anticoagulants		B01AE + B01AF
		Dabigatran	B01AE07
		Rivaroxaban	B01AF01
		Apixaban	B01AF02
		Edoxaban	B01AF03
	Any antiplatelet drugs		B01AC
		Acetylsalicylic acid	B01AC06
		Clopidogrel	B01AC04
		Ticagrelor	B01AC24
		Dipyridamol	B01AC07
Antihypertensives			C02 + C03 + C04 + C07 + C08 + C09
	Beta blockers (all)		C07
	Beta blockers, non-selective		C07AA
	Beta blockers, selective		C07AB
	Beta/alfa blockers		C07AG
	Calcium channel blockers		C08
	ACE inhibitors		C09A + C09B
	Angiotensin II receptor blockers		C09C + C09D
Diuretics		C03 + C09B + C09D	
Lipid lowering drugs			C10
	Statins		C10AA + C10BA + C10BX
	Other lipid lowering drugs		C10AB + C10AC + C10AD + C10AX